Literature DB >> 18566793

[Multimodal therapy for bladder sparing with high grade bladder tumors].

P J Goebell1, W Legal, C Weiss, R Fietkau, B Wullich, S Krause.   

Abstract

The demographic changes of our society, with an increasing number of elderly patients and higher comorbidity, leads to the fact that managing transitional cell carcinoma (TCC) in the elderly is becoming increasingly more important. Thus, the value and indication of conservative or less invasive treatment approaches have to be continuously re-evaluated. The gold standard of treatment for invasive high grade TCC is radical cystectomy with curative intent. However, not each and every patient is suitable for this procedure or the operation is rejected. Thus, alternative treatment options (curative or palliative) including bladder sparing approaches should be offered to this group of patients. These include transurethral resection (TUR-B), open partial cystectomy, chemotherapy (intravesical or systemic), local radiation and minimally invasive interventional therapies alone or in combination. A lower physical and mental burden and, more important, a faster convalescence and the maintenance of the quality of life, are the major aims of these strategies. From an oncologic point of view these concepts have to be viewed with caution, since they may only lead to a temporarily stable disease or the elimination of symptoms. However, long-term follow-up demonstrates that with the correct indication for a multi-modal treatment, a subset of patients with high grade TCC of the bladder may be cured when implementing a bladder sparing approach.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18566793     DOI: 10.1007/s00120-008-1715-4

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  26 in total

Review 1.  [Urinary bladder tumours. The new 2004 WHO classification].

Authors:  M Seitz; D Zaak; R Knüchel-Clarke; C Stief
Journal:  Urologe A       Date:  2005-09       Impact factor: 0.639

Review 2.  Selective bladder preservation by trimodality therapy for patients with muscularis propria-invasive bladder cancer and who are cystectomy candidates--the Massachusetts General Hospital and Radiation Therapy Oncology Group experiences.

Authors:  William U Shipley; Anthony L Zietman; Donald S Kaufman; John J Coen; Howard M Sandler
Journal:  Semin Radiat Oncol       Date:  2005-01       Impact factor: 5.934

3.  Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer.

Authors:  R Sauer; S Birkenhake; R Kühn; C Wittekind; K M Schrott; P Martus
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-01-01       Impact factor: 7.038

4.  Organ-sparing treatment of advanced bladder cancer: a 10-year experience.

Authors:  J Dunst; R Sauer; K M Schrott; R Kühn; C Wittekind; A Altendorf-Hofmann
Journal:  Int J Radiat Oncol Biol Phys       Date:  1994-09-30       Impact factor: 7.038

5.  Radiochemotherapy with cisplatin and 5-fluorouracil after transurethral surgery in patients with bladder cancer.

Authors:  Christian Weiss; Dirk G Engehausen; Frens S Krause; Thomas Papadopoulos; Jürgen Dunst; Rolf Sauer; Claus Rödel
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-04-30       Impact factor: 7.038

6.  Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results.

Authors:  Claus Rödel; Gerhard G Grabenbauer; Reinhard Kühn; Thomas Papadopoulos; Jürgen Dunst; Martin Meyer; Karl M Schrott; Rolf Sauer
Journal:  J Clin Oncol       Date:  2002-07-15       Impact factor: 44.544

7.  Cystoscopy-assisted laparoscopic partial cystectomy.

Authors:  Rajendra B Nerli; Mallikarjun Reddy; Ashish C Koura; Vikram Prabha; Indupur R Ravish; Srisailesh Amarkhed
Journal:  J Endourol       Date:  2008-01       Impact factor: 2.942

8.  Long-term results of orthotopic neobladder reconstruction after radical cystectomy.

Authors:  J N Kulkarni; C S Pramesh; S Rathi; G H Pantvaidya
Journal:  BJU Int       Date:  2003-04       Impact factor: 5.588

Review 9.  Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis.

Authors: 
Journal:  Lancet       Date:  2003-06-07       Impact factor: 79.321

Review 10.  Neoadjuvant chemotherapy for invasive bladder cancer.

Authors: 
Journal:  Cochrane Database Syst Rev       Date:  2005-04-18
View more
  6 in total

1.  An investigation into the cytotoxic effects of 13-acetoxysarcocrassolide from the soft coral Sarcophyton crassocaule on bladder cancer cells.

Authors:  Ching-Chyuan Su; Jui-Hsin Su; Jen-Jie Lin; Cheng-Chi Chen; Wen-Ing Hwang; Han Hsiang Huang; Yu-Jen Wu
Journal:  Mar Drugs       Date:  2011-12-13       Impact factor: 6.085

2.  Three serum metabolite signatures for diagnosing low-grade and high-grade bladder cancer.

Authors:  Guangguo Tan; Haibo Wang; Jianlin Yuan; Weijun Qin; Xin Dong; Hong Wu; Ping Meng
Journal:  Sci Rep       Date:  2017-04-06       Impact factor: 4.379

3.  Identification of an immune-related long non-coding RNA signature and nomogram as prognostic target for muscle-invasive bladder cancer.

Authors:  Yuxuan Song; Donghui Jin; Jingyi Chen; Zhiwen Luo; Guangyuan Chen; Yongjiao Yang; Xiaoqiang Liu
Journal:  Aging (Albany NY)       Date:  2020-06-24       Impact factor: 5.682

4.  Gemcitabine-Resistant Biomarkers in Bladder Cancer are Associated with Tumor-Immune Microenvironment.

Authors:  Yuxuan Song; Yiqing Du; Caipeng Qin; Haohong Liang; Wenbo Yang; Jiaxing Lin; Mengting Ding; Jingli Han; Tao Xu
Journal:  Front Cell Dev Biol       Date:  2022-01-21

5.  Construction and validation of a gene signature related to bladder urothelial carcinoma based on immune gene analysis.

Authors:  Peng Xing; Zhengming Jiang; Yang Liu
Journal:  BMC Cancer       Date:  2022-08-27       Impact factor: 4.638

6.  Gene Expression Profiles Identified Novel Urine Biomarkers for Diagnosis and Prognosis of High-Grade Bladder Urothelial Carcinoma.

Authors:  Yuxuan Song; Donghui Jin; Ningjing Ou; Zhiwen Luo; Guangyuan Chen; Jingyi Chen; Yongjiao Yang; Xiaoqiang Liu
Journal:  Front Oncol       Date:  2020-03-27       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.